Samplix
Herlev
About Samplix
Samplix has developed a proprietary technology - the Xdrop™ technology – for single molecule sample preparation. At the core of the technology is the generation of millions of droplets formed as “water-oil-water”, each droplet constituting a reaction chamber for the handling of single DNA molecules. The Xdrop™ technology comprises both an instrument and related consumables. Samplix enables single DNA molecule sample preparation where today only multi-molecule sample preparation is possible. Among many applications, the Xdrop™ technology allows for targeted enrichment of very large DNA fragments. Samplix addresses customers’ demand for precision, sensitivity and ease of use by overcoming the technical shortcomings of today's technologies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $13.9M
- Last round: Series Unknown (Mar 2023)
- Website: samplix.com
- Phone: +45 20 97 07 63
Industries & Categories
Biotechnology, Information Technology
Social Profiles
Canonical: https://fsome.com/organization/samplix-20055 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.